176 related articles for article (PubMed ID: 25146864)
1. The current state of ototoxicity monitoring in New Zealand.
Steffens L; Venter K; O'Beirne GA; Kelly-Campbell R; Gibbs D; Bird P
N Z Med J; 2014 Jul; 127(1398):84-97. PubMed ID: 25146864
[TBL] [Abstract][Full Text] [Related]
2. Research protocol: Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program.
Paken J; Govender CD; Sewram V
BMC Womens Health; 2017 Dec; 17(1):129. PubMed ID: 29228931
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of hearing in children with solid tumors treated by chemotherapy].
Gryczyńska D; Rychwalska M; Pekacka K; Krawczyński M; Bodalski J
Otolaryngol Pol; 2001; 55(2):179-83. PubMed ID: 11494735
[TBL] [Abstract][Full Text] [Related]
4. Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology.
Garinis AC; Cornell A; Allada G; Fennelly KP; Maggiore RJ; Konrad-Martin D
Int J Audiol; 2018 Sep; 57(sup4):S19-S24. PubMed ID: 28978238
[TBL] [Abstract][Full Text] [Related]
5. Practice of Monitoring Cisplatin-Induced Ototoxicity by Audiology, ENT, and Oncology Specialists: A Survey-Based Study in a Single Italian Medical Center.
Gambacorta V; Orzan E; Faralli M; Gullà M; Lapenna R; Baietta I; De Angelis V; Ricci G
Audiol Res; 2023 Oct; 13(5):779-790. PubMed ID: 37887850
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
7. What Are the Current Audiological Practices for Ototoxicity Assessment and Management in the South African Healthcare Context?
Khoza-Shangase K; Masondo N
Int J Environ Res Public Health; 2020 Apr; 17(7):. PubMed ID: 32290287
[TBL] [Abstract][Full Text] [Related]
8. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
9. Perspectives and practices of ototoxicity monitoring.
Paken J; Govender CD; Pillay M; Sewram V
S Afr J Commun Disord; 2020 May; 67(1):e1-e10. PubMed ID: 32501032
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin ototoxicity in children: implications for primary care providers.
Helt-Cameron J; Allen PJ
Pediatr Nurs; 2009; 35(2):121-7. PubMed ID: 19472677
[TBL] [Abstract][Full Text] [Related]
11. Insight into the current practice of ototoxicity monitoring during cisplatin therapy.
Santucci NM; Garber B; Ivory R; Kuhn MA; Stephen M; Aizenberg D
J Otolaryngol Head Neck Surg; 2021 Mar; 50(1):19. PubMed ID: 33766142
[TBL] [Abstract][Full Text] [Related]
12. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
13. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
[TBL] [Abstract][Full Text] [Related]
14. Current practice of ototoxicity management across the United Kingdom (UK).
Maru D; Malky GA
Int J Audiol; 2018 Sep; 57(sup4):S76-S88. PubMed ID: 29676584
[TBL] [Abstract][Full Text] [Related]
15. Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
Moore B; Sheets G; Doss J; Umrigar A; Norman M; Fang Z; Prasad P; Musso A; Clay S; Tsien F
Am J Audiol; 2023 Sep; 32(3):657-664. PubMed ID: 37532243
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study on the ototoxicity of cisplatin with distortion products].
Orts Alborch M; García Callejo J; Morant Ventura A; Ferrer Baixauli F; Esparcia Navarro M; Marco Algarra J
Acta Otorrinolaringol Esp; 2000; 51(6):469-77. PubMed ID: 11142781
[TBL] [Abstract][Full Text] [Related]
17. Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Womens Health; 2021 Apr; 21(1):164. PubMed ID: 33879158
[TBL] [Abstract][Full Text] [Related]
18. Recovery from cisplatin-induced ototoxicity: a case report and review.
Truong MT; Winzelberg J; Chang KW
Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
[TBL] [Abstract][Full Text] [Related]
19. Cisplatinum ototoxicity in children, long-term follow up.
Al-Khatib T; Cohen N; Carret AS; Daniel S
Int J Pediatr Otorhinolaryngol; 2010 Aug; 74(8):913-9. PubMed ID: 20846503
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting.
Paken J; Govender CD; Pillay M; Sewram V
BMC Health Serv Res; 2022 Jun; 22(1):791. PubMed ID: 35717191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
